September 12, 2016 – Impulse Dynamics, developer of the Optimizer® IVs implantable device for the treatment of Chronic Heart Failure (CHF), is the recipient of the prestigious Frost & Sullivan 2016 European Chronic Heart Failure Therapy New Product Innovation Award.
Based on a recent analysis of the European chronic heart failure therapy market, Frost & Sullivan, a global research and consulting firm with over 50 years of experience identifying innovation and growth opportunities, concluded that Impulse Dynamics’ introduction of Cardiac Contractility Modulation (CCM™) therapy marks an important advancement in the development of therapies for managing various stages of cardiac failure.
CCM™ Therapy is based on delivering non-excitatory electric pulses to the heart muscle to initiate multiple biochemical and neurohormonal changes in the myocardium. As a result, the contractility of the myocardium increases with no concomitant increase in oxygen consumption so that the heart works more efficiently but not harder. CCM™ is delivered by the Optimizer® Device, which has already been successfully launched in Europe and is available in cardiology centers in various countries. CCM™ therapy has been implanted in over 3,000 patients to date and is the only device therapy available for patients with a narrow QRS complex.
“With increasing prescriptions for the therapy, clinical recommendations, and demonstrated improvement in patients’ quality of life, Impulse Dynamics has proven itself to be a game changer in the treatment of chronic heart failure” said Arjunvasan Ambigapathy, Industry Analyst at Frost & Sullivan.
“Receiving the 2016 Product Innovation Award from Frost & Sullivan is a great honor for Impulse Dynamics” said Dr. Simos Kedikoglou, Chief Executive Officer of Impulse Dynamics. “This type of industry recognition is another reaffirmation that CCM™ addresses a significant unmet need in the treatment of chronic heart failure. We are committed to continue to expand the market for CCM™ to benefit heart failure patients world wide“.
The Optimizer® IVs device, which delivers CCM™ therapy, has been successfully launched in Europe and other international markets and is available in a growing number of cardiology centers around the world. The therapy has been implanted in about 3,000 patients to date and is the only device therapy available for patients with a narrow QRS complex. Impulse Dynamics has completed a vast number of clinical studies, including several randomized controlled trials, as published in over 60 publications in leading medical journals. The Optimizer® IVs is limited to investigational use in the United States.
Impulse Dynamics N.V., a member of the Hobart Group companies, is focused on the development of electrical therapies for the treatment of chronic heart failure. As a global leader in cardiac medical innovation, Impulse Dynamics has operations in the United States, Europe, Asia, and Australia. For more information please visit www.impulse-dynamics.com.
The Hobart Group develops and commercializes medical technologies which target top healthcare markets with significant unmet needs. Its growing portfolio of companies covers the areas of cardiology, diabetes, oncology, neurology and rehabilitation. Together, Hobart Group companies have over 200 scientists, engineers, regulatory and business experts across four continents, benefitting from clinical expertise and extensive regulatory and international market knowledge across Europe, the United States and Asia. For more information, visit www.hobart-group.com.
CCM™ and Optimizer® are trademarks of Impulse Dynamics N.V.
Impulse Dynamics Germany GmbH
Tel.: +49 711 220456-0
Fax: +49 711 220456-19